Can you take Duloxetine with Granisetron?

Granisetron has a moderate potential interaction with Arrhythmia.

The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.

DULoxetine has a major potential interaction with Bipolar Disorder.

Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.

DULoxetine has a moderate potential interaction with Bipolar Disorder.

Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.

Granisetron has a moderate potential interaction with Cardiovascular Conditions and Disorders.

The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.

Granisetron has a moderate potential interaction with Constipation.

Granisetron may mask a progressive ileus and/or gastric distention. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction or following recent abdominal surgery. In patients with preexisting constipation receiving subcutaneous granisetron, consider optimizing bowel regimens.

DULoxetine has a moderate potential interaction with Dehydration.

Treatment with SNRI antidepressants can cause hyponatremia. Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.

DULoxetine has a major potential interaction with Depression.

Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.

DULoxetine has a moderate potential interaction with Diabetes Mellitus.

In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes. Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.

Granisetron has a moderate potential interaction with Electrolyte Abnormalities.

The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.

Granisetron has a moderate potential interaction with Gastrointestinal Obstruction.

Granisetron may mask a progressive ileus and/or gastric distention. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction or following recent abdominal surgery. In patients with preexisting constipation receiving subcutaneous granisetron, consider optimizing bowel regimens.

DULoxetine has a moderate potential interaction with Glaucoma, Narrow Angle.

SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.

DULoxetine has a moderate potential interaction with High Blood Pressure.

Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure. Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension. Blood pressure should be assessed prior to initiating treatment and monitored regularly. The dose should be reduced or discontinued if necessary.

DULoxetine has a moderate potential interaction with Hyponatremia.

Treatment with SNRI antidepressants can cause hyponatremia. Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.

DULoxetine has a major potential interaction with Liver Disease.

Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease. The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.

DULoxetine has a moderate potential interaction with Mania.

Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.

Granisetron has a moderate potential interaction with Neutropenia.

Serious or severe injection site reactions have been reported with the subcutaneous formulation of granisetron. Patients who are neutropenic may be at greater risk; monitor for injection site reactions during treatment and consider discontinuing therapy for severe or persistent reactions.

DULoxetine has a major potential interaction with Renal Dysfunction.

The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).

Granisetron has a moderate potential interaction with Renal Dysfunction.

The subcutaneous formulation of granisetron should be avoided in patients with severe renal dysfunction. In patients with moderate renal dysfunction, subcutaneous granisetron should not be administered more frequently than once every 14 days because the clinical significance of potential prolonged elimination of the polymer vehicle is unknown.

DULoxetine has a moderate potential interaction with Seizures.

SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.

DULoxetine has a moderate potential interaction with Urinary Tract Infection.

SNRI antidepressants have a noradrenergic effect and can affect urethral resistance. Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.

DULoxetine has a moderate potential interaction with Urinary Tract Obstruction.

SNRI antidepressants have a noradrenergic effect and can affect urethral resistance. Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.